Now I have all the information needed. Let me write the final consolidated review.

## Summary

CrossNovo proposes a knowledge distillation framework that transfers bidirectional sequence understanding from a Non-Autoregressive Transformer (NAT) to an Autoregressive Transformer (AT) for de novo peptide sequencing. The approach combines joint training with a shared encoder, importance annealing to balance AT/NAT objectives, a cross-decoder attention module that lets the AT attend to NAT latent representations, and gradient blocking to prevent destructive gradient interference. Evaluated on the 9-species benchmark, CrossNovo achieves 0.811 amino acid recall and 0.654 peptide recall, outperforming both the best AT baseline (CasanovoV2: 0.785/0.621) and the NAT baseline (PrimeNovo), and shows particular gains on species where one paradigm previously dominated.

## Strengths

1. **Novel cross-decoder attention mechanism for NAT-to-AT knowledge distillation**: The paper introduces a cross-attention module that replaces the standard cross-attention in the AT decoder, making it attend to both spectrum encoder outputs and NAT decoder latent representations (Section 3.4, Equation with positional encoding split of positions 1–40 for NAT and 41:41+k for spectrum). This is a genuine architectural innovation that goes beyond simple multi-task learning or late fusion.

2. **Gradient blocking with clear motivation**: The paper identifies that naively backpropagating AT loss through the cross-decoder attention harms NAT decoder performance (the CTC objective conflicts with the AT cross-entropy gradient), and proposes gradient blocking via computation-graph detachment to stabilize training (Section 3.4). This addresses a concrete optimization challenge in the proposed framework.

3. **Importance annealing avoids fixed hyperparameter tuning**: Rather than using a static weight for the multitask loss, the linear schedule λ_AT = i/T smoothly shifts from NAT-dominated to AT-dominated optimization (Section 3.3). This is principled — the NAT provides bidirectional signal early, then the AT takes over as the target generator.

4. **Reported results show consistent improvements across two benchmark versions**: On the 9-species-v1 benchmark, CrossNovo achieves 0.811 AA recall and 0.654 peptide recall vs. 0.785/0.621 for the best AT. On the more challenging v2 benchmark, it achieves 0.906 precision and 0.786 peptide recall. The paper demonstrates that CrossNovo inherits strengths from both paradigms — improving over AT by 1–3% on NAT-favored species and extending AT's lead by 9% on AT-favored species (Human, Mouse) (Section 4.3, Table 1).

5. **Honest analysis of distillation direction limitation**: Section 3.5 explicitly discusses why reverse distillation (AT→NAT) would leak ground-truth token information through the causal mask, and why the proposed NAT→AT direction is safe. This shows careful consideration of architectural constraints.

## Weaknesses

### Fatal

None.

### Major

1. **Ablation results absent from the main text**: The paper twice claims that "comprehensive ablation studies validate our key contributions" (Introduction and Conclusion) but provides zero quantitative ablation results in the main text — not even a single sentence summarizing the findings. The reader cannot evaluate whether joint training, importance annealing, cross-decoder attention, and gradient blocking each contribute meaningful gains, or whether the improvements are driven by one component alone. Given that the paper makes distinct architectural claims about multiple components, this is a substantive gap that prevents attribution of performance to the proposed mechanism. (If ablation results exist in an appendix stripped by the parser, the authors should have included a summary in the main text.)

2. **No statistical significance or variance reporting**: All results in Tables 1 and 2 are presented as point estimates with no confidence intervals, standard deviations, or significance tests. For a comparison where many improvements are on the order of 1–3% on individual species, it is impossible to assess whether these reflect robust gains or run-to-run noise. This weakens the claim of "state-of-the-art performance" — though single-run evaluation is common in this field, the paper would be substantially strengthened by reporting mean±std over multiple seeds or bootstrapped intervals.

### Minor

1. **Baseline comparison protocol not fully specified**: The paper states it uses "the same training set" (Section 4.1) but does not explicitly state whether baseline numbers come from direct reimplementation/retraining or from prior publications. It also does not report model parameter counts. Since CrossNovo uses an encoder plus two decoders (AT + NAT), it likely has substantially more parameters than single-decoder baselines, making it unclear whether gains come from the distillation mechanism or simply from added model capacity.

2. **Metric naming inconsistency**: Section 4.2 defines "Peptide precision" as M_pep / T_pep (where T_pep is the total number of peptides in the dataset), which is actually recall (fraction of ground-truth peptides correctly identified), not precision (which would be M_pep / total_predicted_peptides). The results section then correctly refers to this as "peptide recall." The definition in Section 4.2 should be corrected.

3. **No analysis of NAT's fixed-length limitation**: The NAT decoder uses a fixed generation length of 40 (following PrimeNovo). The paper does not report the length distribution of peptides in the test sets or discuss what happens when peptides exceed 40 amino acids — whether the NAT latent representation is truncated and whether this limits distillation's utility for longer peptides.

4. **Hyperparameter sensitivity unexplored**: The importance annealing schedule (linear), learning rate, number of layers, and hidden dimensions are all fixed without exploration. The paper would benefit from at least a brief sensitivity analysis of the annealing schedule shape or starting λ_AT.

5. **"First-ever cross-decoder attention" claim**: Claiming "first-ever" for a cross-decoder attention module is difficult to verify and adds little. The paper should either cite prior uses of cross-attention between different decoders or temper the claim to "to the best of our knowledge" or "in the context of peptide sequencing."

### Trivial

- The abstract states that "AT and NAT baseline models each excel in different types of data prediction" without providing numbers there, but this claim is supported later in Section 4.3. Minor framing issue.
- The paper references "Figure 6" in Section 4.3 but the visible figure numbering shows only Figures 2 and 3 (likely a formatting artifact).

## Nice-to-Haves

- A comparison of the cross-decoder attention design to simpler alternatives (e.g., two separate cross-attention layers, additive combination of encoded features) would strengthen the architectural contribution.
- Demonstrating the approach on a second domain (e.g., a small NLP generation task) would support the claim of broader applicability, though this is not necessary for the paper's primary contribution.
- A brief justification for the sinusoidal encoding of continuous m/z and intensity values (Section 3.2) would help readers unfamiliar with this design choice.

## Removed Points

These points are flagged to be removed; treat them with caution.

- **"The paper should clarify that the goal is to improve AT, not to overcome NAT's defects"** — The paper already states this clearly in the Introduction: "we introduce CrossNovo, a method designed to enhance the performance of autoregressive models in de novo sequencing." This is a strawman; the paper never claims to fix NAT's flaws.
- **"The cross-decoder attention description is ambiguous"** — The paper actually describes the concatenation ("over the sequence length dimension," line 105) and positional encoding scheme (positions 1–40 for NAT, 41:41+k for spectrum, lines 105–106) in reasonable detail. The rationale for separating positions is also given. This criticism overstates the ambiguity.
- **"Sinusoidal encoding for floats is unusual"** — This is a stylistic design preference, not a weakness. The encoding is clearly defined.
- **"The phrase 'extreme optimization difficulties' is vague"** — Minor stylistic nitpick about a perfectly standard descriptive phrase.

## Novel Insights

Beyond the paper's own contributions, the reviews do not surface a genuinely novel insight that the authors missed. The observation that the metric definition in Section 4.2 is mislabeled as "precision" when it is actually recall is the most concrete actionable finding from the review process, but it is a correction rather than a new research direction.

## Suggestions

1. **Add an ablation summary to the main text.** Even a single table on a subset of species (e.g., Human, E. coli) comparing four variants — (a) AT-only, (b) joint training without cross-decoder attention, (c) cross-decoder attention without gradient blocking, (d) full CrossNovo — would directly validate each component and is the single highest-impact fix.

2. **Report variance or acknowledge field-standard limitation.** Provide mean±std over 3–5 random seeds for the primary metrics on at least one benchmark, or bootstrap confidence intervals for the key comparisons. If single-run evaluation is standard in this field, state this explicitly and justify.

3. **Clarify the baseline comparison protocol.** Specify whether all baselines were retrained under the same pipeline or numbers are cited from prior publications. Report approximate parameter counts for all compared models.

4. **Fix the metric naming inconsistency.** Align the definition in Section 4.2 with the terminology used in the results (i.e., correctly label M_pep/T_pep as "peptide recall").

5. **Report peptide length distribution** in the test sets and discuss whether the NAT's fixed length of 40 covers the vast majority of sequences.

## Score and Decision

The paper presents a genuinely novel distillation framework for de novo peptide sequencing with well-motivated architectural innovations (cross-decoder attention, gradient blocking, importance annealing). The reported results show consistent improvements over strong baselines. However, the absence of any ablation results in the main text is a significant gap that prevents readers from attributing performance to the proposed components, and the lack of variance reporting makes it difficult to assess robustness. These issues are addressable in revision but weaken the current submission.

MY FINAL SCORE: <pineapple>5.5</pineapple>
MY FINAL DECISION: <orange>Reject</orange>